Cannabis Science Steps Up the Fight Against Opioid Drug Addictions with its Initial Test Batch of Transdermal Patches and Unisex Rectal Suppositories Available Now in Los Angeles Dispensaries, Meeting a Growing Demand from Self-Medicating Patients
(firmenpresse) - IRVINE, CA -- (Marketwired) -- 07/07/17 -- Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, is pleased to announce initial test batches of Transdermal Patches and Unisex Suppository Regimen packages are now available in two test dispensaries in Los Angeles, California meeting the growing demand for alternative pain medications delivery modules amongst self-medicating patients struggling with several forms of chronic pain management, which the Company firmly believes will directly combat the opioid medication overdose pandemic.
The CBIS Transdermal Patch has been commonly requested by self-medicating patients for almost all different types of chronic pain including fibromyalgia, diabetic nerve pain, neuropathic and many other forms of critical ailments that are associated with chronic pain. One of the advantages is the targeting effect as cannabinoids enter the bloodstream at the affected area through absorption of the skin and formulations are administered when cannabinoids penetrate the central nervous system, providing the self-medicating patient the desired relief.
The CBIS Unisex Suppository Regimen Package is ideal for patients who suffer from cancer treatment side effects like nausea, vomiting, insomnia, anxiety, and severe pain. It also acts as an effective substitute delivery system for patients who may have difficulty ingesting pills or smoking cannabis as rectal absorption produces a higher bioavailability while producing a more consistent effect. The suppositories are the first of three regimen packages that Cannabis Science will release for patients who require alternate delivery methods.
After receiving hundreds of inquiries from eager self-medicating patients and healthcare workers, the company is proud to announce that they are now available for sale at The Kush Factory and Moonlight Cannabis Collective.
The Kush Factory
612 N Vermont
Los Angeles, California 90004
323-219-2827
Moonlight Cannabis Collective
5801 E. Beverly Boulevard
Suite 100
East Los Angeles, CA 90022
(323) 834-9420
Please contact the dispensaries directly for ordering all CBIS products and delivery schedules.
About Cannabis Science, Inc.
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company''s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a ''safe harbor'' for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company is detailed from time to time in the company''s reports filed with the Securities and Exchange Commission.
Cannabis Science, Inc.
Dr. Allen Herman
Chief Medical Officer (CMO)
Tel: 1-888-263-0832
Cannabis Science, Inc.
Mr. Raymond C. Dabney
President & CEO, Co-Founder
Tel: 1-888-263-0832
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 07.07.2017 - 07:17 Uhr
Sprache: Deutsch
News-ID 1512603
Anzahl Zeichen: 3608
contact information:
Contact person:
Town:
IRVINE, CA
Phone:
Kategorie:
Alternative
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 573 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Cannabis Science Steps Up the Fight Against Opioid Drug Addictions with its Initial Test Batch of Transdermal Patches and Unisex Rectal Suppositories Available Now in Los Angeles Dispensaries, Meeting a Growing Demand from Self-Medicating Patients
"
steht unter der journalistisch-redaktionellen Verantwortung von
Cannabis Science, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
